ArticleBritish journal of clinical pharmacology2026
Anticholinergic burden interacts with age and AIDS history to amplify frailty in people with HIV.
Article in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Comment on revisiting the association between anticholinergic burden and frailty in people with HIV.British journal of clinical pharmacology · 2026Article
- Reply to: Comment on revisiting the association between anticholinergic burden and frailty in people with HIV.British journal of clinical pharmacology · 2026Article
- Anticholinergic burden interacts with age and AIDS history to amplify frailty in people with HIV.British journal of clinical pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn ageing people with human immunodeficiency virus (HIV), frailty, multimorbidity and polypharmacy are prevalent. Anticholinergic medications are commonly prescribed in this population and are associated with adverse physical and cognitive outcomes, yet their contribution to frailty phenotypes remains insufficiently characterized.
methodsWe conducted a cross-sectional study of people with HIV receiving care at a tertiary HIV clinic in Northern Italy. Anticholinergic burden (ACB) was quantified using the Anticholinergic Cognitive Burden scale. Frailty was assessed using the modified Fried phenotype and the deficit-accumulation Rockwood index. Multivariable linear models with interaction terms (IT) and perturbation analyses were used to evaluate independent associations between ACB and frailty scores and to assess effect modification by demographics and clinical factors.
resultsA total of 1200 participants were included (mean age of 52 ± 12 years; 95.5% with HIV-RNA < 50 copies/mL; 19.0% receiving anticholinergic medications). By Fried criteria, 38.7% were pre-frail and 6.9% frail, with Rockwood score increasing stepwise across these groups. ACB was among the strongest independent correlates of frailty (Fried: aβ 0.32 [0.25-0.40], p < .001; Rockwood: aβ 0.69 [0.61-0.77], p < .001), alongside age and chronic kidney disease. With the Fried phenotype, the impact of ACB significantly intensified with age (IT aβ 1.17, p < .001), prior acquired immunodeficiency syndrome (AIDS) (IT aβ 0.35, p < .001) events and longer HIV duration (IT aβ 0.16, p = .023).
conclusionsACB is a modifiable contributor to frailty in people with HIV, with disproportionate impact on older individuals and those with prior severe immunosuppression. Incorporating routine ACB assessment and deprescribing strategies into HIV care may help support functional ageing and reduce vulnerability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.